Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06614322 · ClinicalTrials.gov registry record · Phase 2
SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.
A Phase 2 study, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT06614322 is a Phase 2 study that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 190 participants.
The verdict
NCT06614322, a Phase 2 study, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy. The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC). This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks. Participants will: * Undergo a quantitative sensory testing (QST) exam. * Provide a blood sample. * Complete questionnaires on the computer. * Take the study drug as instructed.
Interventions
- OTHER Placebo
- DRUG Duloxetine
- DRUG Pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2026-01-29 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06614322
The ClinicalTrials.gov registry entry for NCT06614322 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06614322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06614322 about?
NCT06614322 is a clinical study titled "SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.". The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy. The analgesic effect is evaluated by ...
What is the current status of trial NCT06614322?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2026-01-29. Estimated completion is 2028-06.
What interventions are being tested in trial NCT06614322?
The interventions under investigation include: Placebo (OTHER), Duloxetine (DRUG), Pregabalin (DRUG).
Who is sponsoring clinical trial NCT06614322?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.